Investigation of the efficacy and tolerability of Dr Michaels(R) (also branded as Eczitinex(R) and Itchinex Eczitinex(R)) topical products in the treatment of atopic dermatitis in children

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F16%3A10375023" target="_blank" >RIV/00216208:11130/16:10375023 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Investigation of the efficacy and tolerability of Dr Michaels(R) (also branded as Eczitinex(R) and Itchinex Eczitinex(R)) topical products in the treatment of atopic dermatitis in children

Original language description

Atopic eczema is a chronic relapsing inflammatory skin disorder, characterized clinically by intensely pruritic eczematous skin lesions and a defective epidermal barrier. It affects more than 15% of children and up to 10%of adults, which makes the disease a social health problem still without a challenging treatment. The aim of this study was to evaluate the efficacy and tolerability of Dr Michaels(R) (Eczitinex(R)) topical product family in the treatment of atopic dermatitis in children. We studied a group of 30 patients (17 female, 13 male), aged 5 to 13 (mean age: 9), affected by atopic dermatitis since they were newborn. All patients had been unsuccessfully treated with conventional anti-inflammatory therapies and ceased treatment 2 weeks before commencing research. The patients were treated with Dr Michaels(R) (Eczitinex(R) and Itchinex(R)) product family including a moisturising bar, topical ointment and PSC 900 oral herbal formulation. The treatment was evaluated clinically and photographically at 0, 1, 2, 4, 6, 8, 10, 12, and 14 weeks. Twenty-eight patients showed a significant improvement of cutaneous rashes and pruritus on the first week of treatment, with a complete remission at 10-12 weeks. Only two patients, brother and sister respectively, showed a slow response to treatment and reported an increasing itching. Following 14 weeks of treatment with the Dr Michaels(R) (Eczitinex(R) and Itchinex(R)) product family, patients demonstrated complete resolution of their AD. All patients showed a marked improvement in their condition within 3 days of treatment with most of the lesions and symptoms totally resolved within 10 to 12 weeks of treatment with Dr Michaels(R) (Eczitinex(R) and Itchinex(R)) family of products. This clinical report highlights that the Dr Michaels(R) (Eczitinex(R) and Itchinex(R)) product family is a safe and effective treatment option for AD.

Czech name

—

Czech description

—

Type

J_SC - Article in a specialist periodical, which is included in the SCOPUS database

CEP classification

—

OECD FORD branch

30216 - Dermatology and venereal diseases

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of Biological Regulators and Homeostatic Agents

ISSN

0393-974X

e-ISSN

—

Volume of the periodical

30

Issue of the periodical within the volume

2 Suppl 3

Country of publishing house

IT - ITALY

Number of pages

9

Pages from-to

55-63

UT code for WoS article

—

EID of the result in the Scopus database

2-s2.0-85044153122